Company Overview and News

302
Your Daily Pharma Scoop: Iovance Zooms Ahead, Palatin Surges And Deciphera Moves Up

2018-06-06 seekingalpha
Iovance Biotherapeutics (NASDAQ:IOVA) is a small biopharma with about $1.3bn in market cap. This is our well-known Lion Bio which shot to some prominence last year and also changed its name to Iovance. Their lead product candidate is LN-144, an adoptive cell therapy in Phase 2 trial in metastatic melanoma using tumor-infiltrating lymphocytes (‘TIL). These are T cells derived from the patients' tumors.
NKTR DCPH VXRT LOXO NWBO PODD MRSN SHPG BPMC MYL IMMU IDRA IOVA CTMX KITE CYHHZ BMY CYH AMAG GILD NWBOW PTN PDM K JNCE MRK GHDX ALNY

0
Piedmont Office (PDM) Presents At NAREIT REITweek: 2018 Investor Conference - Slideshow

2018-06-05 seekingalpha
The following slide deck was published by Piedmont Office Realty Trust in conjunction with this event.
PDM

0
PDM / Piedmont Office Realty Trust, Inc. 8-K (Current Report)

2018-05-23 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
PDM

0
Piedmont Office Realty Trust's (PDM) CEO Don Miller on Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
Piedmont Office Realty Trust Inc. (NYSE:PDM) Q1 2018 Earnings Conference Call May 2, 2018 10:00 AM ET
PDM

0
PDM / Piedmont Office Realty Trust, Inc. DEF 14A

2018-03-26 sec.gov
tv488671_def14a - none - 3.520643s TABLE OF CONTENTS
PDM

0
PDM / Piedmont Office Realty Trust, Inc. DEFA14A

2018-03-26 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION <
PDM

0
PDM / Piedmont Office Realty Trust, Inc. PRE 14A

2018-03-15 sec.gov
tv488350_pre14a - none - 4.0128494s TABLE OF CONTENTS
PDM

162
Orexigen, Advaxis Tumble into Tuesday’s 52-Week Low Club

2018-03-13 247wallst
March 13, 2018: Here are four stocks trading with heavy volume among 36 equities making new 52-week lows in Tuesday’s session. On the NYSE decliners led advancers by about 3 to 2 and on the Nasdaq, decliners led advancers by about 9 to 5.
GSAT ADXSW OREX ADXS PDM

28
Piedmont Office Realty Trust downgraded to sell from hold at Stifel Nicolaus

2018-03-13 marketwatch
Piedmont Office Realty Trust Inc (PDM) Files 10-K for the Fiscal Year Ended on December 31, 2017
ARE ARE.PRD BXP.PRB BXP PDM ARE.PRE DEA

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 720190206